What is the key reducing equivalent required for lipogenesis and generates Nicotinamide adenine dinucleotide phosphate (NADPH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The key reducing equivalent required for lipogenesis is NADPH, which is generated through various pathways, including the pentose phosphate pathway, with serine catabolism playing a crucial role in liver NADPH production, as evidenced by a recent study 1.

Importance of NADPH in Lipogenesis

NADPH serves as the essential electron donor for reductive biosynthesis of fatty acids, providing the reducing power needed to convert acetyl-CoA to fatty acids during lipogenesis. The primary sources of NADPH in the body include:

  • The pentose phosphate pathway
  • Malic enzyme
  • Isocitrate dehydrogenase The pentose phosphate pathway is particularly important, generating NADPH when glucose-6-phosphate is oxidized by glucose-6-phosphate dehydrogenase, and again when 6-phosphogluconate is oxidized by 6-phosphogluconate dehydrogenase.

Role of Serine Catabolism in Liver NADPH Production

A recent study published in Nature Metabolism 1 found that serine catabolism generates liver NADPH and supports hepatic lipogenesis. This study used stable isotope tracing in mice to show that de novo lipogenesis in adipose is supported by glucose and its catabolism via the pentose phosphate pathway to make NADPH, while the liver derives acetyl-CoA for lipogenesis from acetate and lactate, and NADPH from folate-mediated serine catabolism.

Clinical Implications

Understanding the role of NADPH in lipogenesis and the various pathways involved in its production is crucial for the development of therapeutic strategies aimed at modulating lipid metabolism. For example, inhibiting SHMT, a key enzyme involved in serine catabolism, may decrease hepatic lipogenesis, as shown in the study 1. This highlights the potential for tissue-specific pharmacological interventions targeting the pentose phosphate pathway and serine catabolism to modulate lipid metabolism and treat related disorders.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.